Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NeoMed, Inc.
Asia Deal Watch: Kelun Partners With Merck A Third Time, Optioning Rights To Seven ADCs
Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.
Tech Transfer Roundup: Deerfield, Broad Institute Alliance Selects Two Cancer Programs
An alliance of Deerfield and the Broad Institute to accelerate research into high-mortality diseases identifies its first two research projects, while Janssen and UPenn look into gene therapy for Alzheimer's disease.
Tech Transfer Roundup: Ohio State Turns To Industry Exec To Optimize Assets Before A Deal
Jeffrey Patrick joins Ohio State's effort to develop cancer drugs from internal research, bringing a biopharma viewpoint to optimizing such programs before the deal-making effort starts. Plus, the EMA sets a framework for academic interaction, and more tech transfer news.
Protez Pharmaceuticals Inc.
The menace of drug resistant bacteria continues to grow. As Big Pharma has exited early-stage antibacterial R&D in recent years, start-ups like Protez Pharmaceuticals have filled the void.
- Medical Devices
- Consumables, Central Supplies
- Infusion Therapy Equipment and Supplies
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.